Veterinary Biologics Market Size & Share Analysis - Growth, Trends, And Forecasts (2025 - 2030)

The Veterinary Biologics Market Report is Segmented by Product Type (Vaccines, Bacterins, Antisera, Diagnostic Kits, and Others), by Animal (Companion Animal (Canine, Avian, and Feline), Livestock Animal (Aquatic, Bovine, Porcine, Ovian, and Poultry), and Equine), by Distribution Channel (Veterinary Clinics, Veterinary Hospitals, and Retail Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Veterinary Biologics Market Size & Share Analysis - Growth, Trends, And Forecasts (2025 - 2030)

Veterinary Biologics Market Size

Veterinary Biologics Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 16.08 Billion
Market Size (2030) USD 21.71 Billion
CAGR (2025 - 2030) 6.20 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Veterinary Biologics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Veterinary Biologics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Veterinary Biologics Market Analysis

The Veterinary Biologics Market size is estimated at USD 16.08 billion in 2025, and is expected to reach USD 21.71 billion by 2030, at a CAGR of 6.20% during the forecast period (2025-2030).

Rising demand for veterinary biologics, driven by the need to manage infectious diseases and advancements in genomics, is fueling market growth. Additionally, the increasing adoption of regenerative medicine is further supporting this expansion. Companies in the market are implementing strategies to strengthen their presence in developing economies and leverage untapped opportunities in these regions. Companies are pouring investments into state-of-the-art technologies, aiming to boost product performance, reliability, and overall user experience. Such advancements not only draw in new clientele but also ensure the loyalty of current customers by adapting to their changing needs. 

Advancements in genomics is a driving factor for veterinary biologics market. As of June 2023, Researchers acknowledged two pivotal advancements in gene editing which included regulatory approval for pork derived from gene-edited pigs to enter the human food supply and the development of a calf with enhanced resistance to bovine viral diarrhea virus (BVDV). The Food and Drug Administration (FDA) announced a strategic collaboration with the National Institute of Standards and Technology (NIST) to develop a comprehensive resource aimed at supporting organizations innovating in animal biotechnology, particularly through the application of gene editing to modify animal genomes. Such advancements provide breakthrough solutions for animal health, in turn driving the demand for veterinary biologics market. 

Globally, the rise in animal-related infectious diseases is contributing to the growth of the veterinary biologics market. The U.S. Centers For Disease Control and Prevention (CDC) reported in March 2023 that over 60% of known infectious diseases in humans originate from animals, and 75% of newly emerging diseases also have animal origins. This highlights the CDC's ongoing efforts to address zoonotic diseases in the United States and globally. The growing prevalence of infectious diseases, such as avian flu, further drives the market. As of December 2024, the H5N1 avian flu, which initially emerged in Europe in 2020, has significantly impacted wildlife and livestock, affecting over 10,000 wild birds, 125 million poultry, and 875 dairy herds across various states. The virus has also impacted 485 bird species and 48 mammal species, causing fatalities among diverse animals, including seals, dolphins, bald eagles, and even a zoo tiger. These developments are expected to boost the veterinary biologics market further. 

The rising demand for regenerative medicine is also a key factor driving the veterinary biologics market. Regenerative medicine in animal health involves therapies to repair, replace, or regenerate damaged tissues and organs. These therapies are also used to address chronic conditions such as arthritis, sprains, and other injuries. A critical component of veterinary regenerative medicine is mesenchymal stromal cells (MSCs), part of the body's repair system. Research published by the National Institutes of Health (NIH), in March 2022, demonstrated the successful application of autologous MSCs in dogs and rabbits for treating chondral defects and promoting bone regeneration. Porcine and equine are emerging as promising models for further studies, which are expected to support market growth. 

However, the market faces critical challenges due to the stringent regulations imposed by the government. 

Veterinary Biologics Industry Overview

The veterinary biologics market is fragmented due to the presence of several manufacturers operating globally and regionally. Some of the leading players in the market are Boehringer Ingelheim, Ceva, Elanco Animal Health, Hester Biosciences Limited, and Meiji Animal Health Co., Ltd, amongst others. 

Veterinary Biologics Market Leaders

  1. Boehringer Ingelheim

  2. Ceva

  3. Elanco Animal Health

  4. Hester Biosciences Limited

  5. Meiji Animal Health Co., Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Veterinary Biologics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Veterinary Biologics Market News

  • October 2024: Vetlen Advanced Veterinary Devices unveiled its latest innovation which is a device designed to administer antibiotic medication straight to infected surgical and wound sites in dogs and horses. Named as "Vetlen Pouch," this novel drug delivery system provides a fresh approach to delivering concentrated, daily antibiotic treatments directly to infected wounds in canines and equines.
  • May 2024: Merck Animal Health announced that it had received approval from the U.S. Department of Agriculture (USDA) for its NOBIVAC NXT Canine Flu H3N2. This innovative product is designed to address the ongoing risk of canine influenza. The product is available in veterinary clinics and hospitals nationwide.

Veterinary Biologics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advancements in Genomics
    • 4.2.2 Rising Cases of Infectious Diseases
    • 4.2.3 Increasing Demand For Regenerative Medicine
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations Imposed By The Government
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Product Type
    • 5.1.1 Vaccines
    • 5.1.2 Bacterins
    • 5.1.3 Antisera
    • 5.1.4 Diagnostic Kits
    • 5.1.5 Others
  • 5.2 By Animal
    • 5.2.1 Companion Animals
    • 5.2.2 Livestock
    • 5.2.3 Equine
  • 5.3 By Distribution Channel
    • 5.3.1 Veterinary Clinics
    • 5.3.2 Veterinary Hospitals
    • 5.3.3 Retail Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boehringer Ingelheim
    • 6.1.2 Ceva
    • 6.1.3 Elanco Animal Health
    • 6.1.4 Hester Biosciences Limited
    • 6.1.5 Meiji Animal Health Co., Ltd.
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Phibro Animal Health Corporation
    • 6.1.8 Virbac
    • 6.1.9 WuXi Biologics
    • 6.1.10 Zoetis Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Veterinary Biologics Industry Segmentation

As per the report’s scope, veterinary biologics are products developed to diagnose, manage, or prevent animal diseases. These include vaccines, antibody-based treatments, and diagnostic test kits. Derived from living organisms and biological processes, veterinary biologics function through immunological mechanisms.

The veterinary biologics market is segmented by product type, animal, and distribution channel. By product type, the market has been segmented into vaccines, bacterins, antisera, diagnostic kits, others. Others include growth promoters & allergenic extracts. Based on animal, the market is segmented into companion animals, livestock, and equine. Companion animals have been further segmented into canine, avian, and feline. Livestock segment have been segmented into aquatic, bovine, porcine, ovine, and poultry. By distribution channel, the market covers veterinary clinics, veterinary hospitals, and retail pharmacies. Geographically, the market includes North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. The report details market size and forecasts for 17 countries across these regions, with valuations presented in USD.

By Product Type Vaccines
Bacterins
Antisera
Diagnostic Kits
Others
By Animal Companion Animals
Livestock
Equine
By Distribution Channel Veterinary Clinics
Veterinary Hospitals
Retail Pharmacies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Veterinary Biologics Market Research FAQs

How big is the Veterinary Biologics Market?

The Veterinary Biologics Market size is expected to reach USD 16.08 billion in 2025 and grow at a CAGR of 6.20% to reach USD 21.71 billion by 2030.

What is the current Veterinary Biologics Market size?

In 2025, the Veterinary Biologics Market size is expected to reach USD 16.08 billion.

Who are the key players in Veterinary Biologics Market?

Boehringer Ingelheim, Ceva, Elanco Animal Health, Hester Biosciences Limited and Meiji Animal Health Co., Ltd are the major companies operating in the Veterinary Biologics Market.

Which is the fastest growing region in Veterinary Biologics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Veterinary Biologics Market?

In 2025, the North America accounts for the largest market share in Veterinary Biologics Market.

What years does this Veterinary Biologics Market cover, and what was the market size in 2024?

In 2024, the Veterinary Biologics Market size was estimated at USD 15.08 billion. The report covers the Veterinary Biologics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Veterinary Biologics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.